Browsing Tag
Sanofi
62 posts
Regeneron’s Libtayo wins FDA approval as first adjuvant immunotherapy for high-risk skin cancer patients
Find out how Regeneron’s Libtayo is redefining skin cancer care as the first FDA-approved adjuvant immunotherapy for high-risk CSCC patients
Sanofi taps Novavax’s Matrix-M for flu: Is NVAX stock finally turning a corner?
Novavax (NASDAQ: NVAX) expands Sanofi partnership, granting rights to Matrix-M adjuvant for pandemic flu candidates. See stock impact and outlook.
How recombinant therapies are reshaping bleeding disorder treatment for children in 2025
Recombinant therapies are replacing plasma-derived treatments for pediatric bleeding disorders—see what’s driving this shift in 2025 and who’s leading.
Daiichi Sankyo launches development of oral triple combination tablets for LDL cholesterol management in Europe
Daiichi Sankyo (TYO: 4568) begins developing oral triple therapy with bempedoic acid, ezetimibe, and statins to transform LDL cholesterol management in Europe.
Unisom partners with Julian Edelman to tackle fantasy football stress with sleep-first strategy
Unisom joins forces with Julian Edelman to launch Sleeper Pickz, linking fantasy football advice with better sleep. Find out how this campaign redefines rest.
Can Sanofi turn molecular clamp technology into a global respiratory vaccine platform beyond RSV?
Can Sanofi turn Vicebio’s molecular clamp tech into a global respiratory vaccine platform? Analysts see multi-pathogen potential beyond RSV by 2030.
How much could Vicebio’s $1.15bn acquisition add to Sanofi’s RSV market share by 2030?
Can Sanofi’s $1.15B Vicebio deal help it win 10% of the RSV market by 2030? Analysts weigh in on how combination vaccines could change respiratory care.
What makes molecular clamp technology attractive for future combination respiratory vaccines?
Can molecular clamp technology make combination respiratory vaccines more practical than mRNA? Learn how Sanofi plans to use it for multi-pathogen protection.
Is Sanofi creating a template for biopharma bolt-on deals with its Vicebio acquisition?
Is Sanofi setting a new standard for biopharma bolt-on deals with its $1.15B Vicebio acquisition? Find out how this strategy could shape future M&A.
Will Vicebio’s VXB-241 and VXB-251 give Sanofi an edge in older adult respiratory protection?
Can Sanofi’s VXB-241 and VXB-251 vaccines protect older adults better than single-pathogen RSV shots? Explore how they could reshape respiratory care.